CBLB Regulates MAPK‐P38 Pathway via MAP3K9 Ubiquitination to Inhibit GBM Cell Invasion and Migration
Journal of Cellular Physiology · 2025
DOI: 10.1002/jcp.70037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Physiology, 2025. Verfasst von Yuankun Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China. Hauptthemen laut MEDLINE: Cell Movement, Glioblastoma, Proto-Oncogene Proteins c-cbl, MAP Kinase Kinase Kinases. Die Arbeit nennt 40 Literaturangaben. Gefördert von: This study was supported by the Wuxi Taihu Lake Talent Plan-Supports for Leading Talents in Medical and Health Profession (2020THRC-DJ-SNW), the Key Project of….
Abstract (Originalsprache)
Glioma cells exhibit high invasiveness and have the ability to evade surgical resection, radiotherapy, and chemotherapy, which are major factors contributing to the challenges in effective treatment and recurrence. The ubiquitin‐proteasome system (UPS) plays a crucial role in posttranslational modification, significantly contributing to the aggressive progression of glioblastoma (GBM). This study identified the E3 ubiquitin ligase CBLB as a crucial and abnormally regulated component of the UPS in GBM, noting its significant downregulation compared to normal brain tissue and its negative correlation with malignant phenotypes and poor prognosis. Experimental studies, both in vitro and in vivo, have shown that CBLB can inhibit the migration and invasion of GBM cells. Mechanistically, CBLB directly interacts with MAP3K9 through its RING domain, leading to K48‐K63‐linked polyubiquitination at the Lys 193 site, thereby promoting MAP3K9 proteasomal‐mediated degradation. MAP3K9 downregulation suppresses MAPK‐P38 pathway activation. This study identifies CBLB as a tumor suppressor that modulates the MAPK‐P38 signaling pathway by promoting the polyubiquitination and degradation of MAP3K9, offering a new therapeutic approach for GBM treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
- Wuxi Medical Center of Nanjing Medical University, Wuxi, China.
- Center of Clinical Research, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
ORCID-Profile: Yuankun Liu
Förderung
- This study was supported by the Wuxi Taihu Lake Talent Plan-Supports for Leading Talents in Medical and Health Profession (2020THRC-DJ-SNW), the Key Project of…
Zitieren
APA
Liu, Y., Ni, K., Zhao, S., Zhao, J., Zhong, M., Cheng, C., Ji, W., Jiao, J., & Shao, J. (2025). CBLB Regulates MAPK‐P38 Pathway via MAP3K9 Ubiquitination to Inhibit GBM Cell Invasion and Migration. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.70037
Vancouver
Liu Y, Ni K, Zhao S, Zhao J, Zhong M, Cheng C, et al. CBLB Regulates MAPK‐P38 Pathway via MAP3K9 Ubiquitination to Inhibit GBM Cell Invasion and Migration. Journal of Cellular Physiology. 2025. doi:10.1002/jcp.70037
BibTeX
@article{Liu2025,
author = {Liu, Yuankun and Ni, Kaixiang and Zhao, Songyun and Zhao, Jingjing and Zhong, Mengmeng and Cheng, Chao and Ji, Wei and Jiao, Jiantong and Shao, Junfei},
title = {CBLB Regulates MAPK‐P38 Pathway via MAP3K9 Ubiquitination to Inhibit GBM Cell Invasion and Migration},
journal = {Journal of Cellular Physiology},
year = {2025},
doi = {10.1002/jcp.70037}
}
EUVIMED